PPT-Sofosbuvir in HCV-

Author : mitsue-stanley | Published Date : 2017-05-29

HIV Coinfection amp HCV GT 123 PHOTON1 Trial Phase 3 Sulkowski MS et al JAMA 201431235361 Treatment Naïve and Treatment Experienced HIV Coinfection Source Sulkowski

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Sofosbuvir in HCV-" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Sofosbuvir in HCV-: Transcript

HIV Coinfection amp HCV GT 123 PHOTON1 Trial Phase 3 Sulkowski MS et al JAMA 201431235361 Treatment Naïve and Treatment Experienced HIV Coinfection Source Sulkowski MS et al JAMA 201431235361. ELECTRON (Overview): 6 parts, 22 arms. Phase . 2. Treatment. Naïve and Treatment . Experienced. Source: . Gilead Sciences, . Inc. Sofosbuvir. Summary of ELECTRON Trials Design (1 of 2). Part 1 . - . (. Epclusa. ). Prepared by. : H. Nina Kim, MD MSc and David . Spach. , MD. Last . Updated: . July . 8, . 2016. Background and Dosing. Sofosbuvir-Velpatasvir. (. Epclusa. ). Sofosbuvir-Velpatasvir. (. . and HIV Coinfection. NIAID ERADICATE Trial. Phase . 2a. Treatment. Naïve and Treatment . Experienced. Osinusi. . A, et al. JAMA. 2015;313:1232-9. . HIV Coinfection. Source: . Osinusi. A, et al. . Genotype . 2. . or 3 . FUSION. Trial. Phase . 3. *Note: Published . in . NEJM in tandem . with . POSITRON Trial (GT 2,3 Unable to receive PEG). Treatment. . Experienced. Jacobson I, et al. N . Engl. ION-4. Phase . 3. Treatment. Naïve and Treatment . Experienced. Naggie. S, . et al. . N . Engl. J Med 2015;378:705-13.. HIV Coinfection. Source: . Naggie. S, et al. N . Engl. J Med 2015;378:705-13.. VALENCE Trial. Phase . 3. Treatment. Naïve and Treatment . Experienced. Zeuzem. S, et al. . N . Engl. J Med. 2014;370:1993-2001. Source: . Zeuzem. S, et al. N . Engl. J Med. 2014;370:1993-. 2001.. . or 3 . LONESTAR-2. Phase 2. Treatment. . Experienced. Lawitz. . E, et al. . Hepatology. . 2015:61:769-75.. Source: . Lawitz. E, et al. . Hepatology. . . 2015:61:769-75.. Sofosbuvir + . PEG + RBV . in Genotype 3. ASTRAL-3. Phase 3. . Treatment. . Naïve & Experienced. Foster GR, . et al. . N . Engl. J Med. . 2015. ;373:2608-17.. *Published in tandem with ASTRAL-2 Trial. Source: Foster GR, . ASTRAL-2*. Phase 3. . Treatment. . Naïve & Experienced. Foster GR, . et al. . N . Engl. J Med. . 2015. ;373:2608-17.. *Published in tandem with ASTRAL-3 Trial. Source: Foster GR, . et al. N . ASTRAL-1. Phase 3. . Treatment. . Naïve & Experienced. Feld JJ, . et al. . N . Engl. J Med. . 2015. ;373:2599-607.. Source: Feld . JJ. , et al. N . Engl. J Med. . 2015. ;373:2599-607.. Sofosbuvir-Velpatasvir. SOLAR-1 (Cohorts A and B). Phase . 2 . Treatment Naïve and Treatment Experienced. Charlton M, al. Gastroenterology. 2015; 149:649-59.. Source: Charlton M, . et al. . Gastroenterology. 2015; 149:649-59.. NIAID Retreatment. Phase . 2a . Treatment. . Experienced. Osinusi. A, . et al. . Ann Intern Med. 2014;161:634-8.. Source: . Osinusi. A, et al. Ann Intern Med. 2014;161:634-8.. Ledipasvir-Sofosbuvir Retreatment of SOF RBV Failure in HCV GT 1. . with Advanced Liver Disease. ALLY-3+ Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Leroy V, . et al. . Hepatology 2016;63:1430-41.. Source: Leroy V, et al. Hepatology . 2016;63:1430-41.. Following Liver Transplantation. Phase 2. Charlton M, . et al. . Gastroenterology. 2015;148:108-17.. Treatment. Naïve and Treatment . Experienced. Liver Transplantation. Source: Charlton M, et al. Gastroenterology. 2015;148:108-17..

Download Document

Here is the link to download the presentation.
"Sofosbuvir in HCV-"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.